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of cell movement and adhesion by linking 
integrins and scaffold proteins to the actin 
cytoskeleton and the extracellular matrix 
(ECM).[1,2]
During the past decade, TNS4 has been 
suggested as a putative oncogene due to 
its overexpression in a vast range of cancer 
types: breast,[3] colorectal,[4,5] hepatocellular 
carcinoma,[6] melanoma,[7] oesophagogas-
tric adenocarcinoma,[8] gastric,[9,10] pancre-
atic,[5] thymoma,[11] and lung cancer.[12]
Even though TNS4 has been identified 
as an oncogene in a number of cancers, 
the mechanisms regulating its role in 
motility, invasion, and metastasis are still 
under investigation.
In colorectal cancer (CRC) cell lines, 
TNS4 has been shown to induce epithe-
lial to mesenchymal transition (EMT) 
by repressing E-cadherin and to signifi-
cantly increase migration and invasion.[4] 
More recently, a role for TNS4 in selec-
tively mediating TGF-ß-induced EMT in 
CRC cell lines has been reported. In the 
absence of TNS4, the effects of TGF-ß stimulation on inducing 
motility and invasion were abrogated, but TGF-ß-induced pro-
liferation was not affected.[13] Furthermore, TNS4-mediated Src 
stabilization was found to be the responsible for EMT induction 
in CRC cell lines [14] Nude mice receiving a splenic injection of 
TNS4 overexpressing HCT116 cells have produced larger splenic 
tumors and hepatic metastatic nodules compared to the con-
trol group.[15] However, thus far, studies demonstrating the role 
of TNS4 in syngeneic or immunocompetent animal models of 
CRC invasion and metastasis in vivo are still lacking.
The use of 3D in vitro models may fill in this gap by providing 
an enriched tumor microenvironment with improved cell interac-
tions and ECM which better mimics the in vivo context and which 
may provide a better measure of drug response.[16–20] Amongst 
the 3D in vitro models available for CRC, recellularized CRC scaf-
folds have been suggested as a useful preclinical patient-derived 
tool that could predict in vitro the success of future therapies 
administered to the patient.[21] However, due to its uniqueness 
and complexity, this method may not be as practical as heterotypic 
spheroids for drug screening. Addition of stromal cell types such 
as cancer-associated fibroblasts (CAFs) to 3D models substantially 
supports growth of cancer cell lines and may also promote inva-
sion and metastasis by guiding cancer cells at the invasive edge.[22] 
Interactions between tumor and stroma are difficult to study in 
vivo due to limitations in tissue accessibility, in vivo monitoring 
and selection of specific intercellular interactions.[23]
TNS4 (Tensin 4 or Cten) is a putative oncogene in colorectal cancer (CRC) with a 
role in regulating cell adhesion, motility, invasion, and epithelial to mesenchymal 
transition (EMT). The objective is to study the role of TNS4 in CRC using more 
realistic models of the tumor microenvironment. CRC cells expressing TdTomato 
protein and shTNS4/shLUC hairpin oligos are grown in 3D spheroids with and 
without cancer-associated fibroblasts (CAFs). Adhesiveness to collagen I and 
CAFs is assessed in 2D and cell proliferation, volume, and invasion are assessed 
in 3D conditions. The role of TNS4 knockdown in gefitinib chemosensitivity and 
epidermal growth factor receptor (EGFR) and Ras protein levels are also tested. 
In general, TNS4 knockdown increases cell proliferation in cell lines producing 
compact spheroids. The addition of CAFs in spheroids supports CRC cell prolif-
eration, whereas CAFs themselves do not proliferate, but increases ECM degra-
dation. TNS4 knockdown reduces adhesiveness and 3D invasion and disrupts 
EGFR signaling which results in increased sensitivity to Gefitinib. In conclusion, 
in a 3D spheroid model, TNS4 inhibits cell proliferation and promotes cell inva-
sion into the ECM, possibly by adhesion to the ECM and stromal cells. TNS4 
knockdown enhances sensitivity to the EGFR inhibitor gefitinib and may be 
helpful for Kirsten ras oncogene homolog mutant CRC patients.
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1. Introduction
TNS4 (tensin4) or Cten (C-terminal tensin-like) is a tensin local-
ized to focal adhesion sites where it has a role in the dynamics 
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
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Commons Attribution License, which permits use, distribution and 
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In this study we aim first to explore the role of TNS4 in het-
erotypic interactions between cancer cells and CAFs within the 
in vitro 3D spheroid tumor microenvironment, and second to 
validate the role of TNS4 in CRC proliferation and invasion 
in the same model. To this end, we have used stable lentiviral 
TNS4 and Luciferase control knockdowns of CRC cell lines 
expressing TdTomato fluorescent protein, alone or with cancer-
associated fibroblasts in mixed spheroids. Expression of fluo-
rescent TdTomato was used to measure the growth of CRC cells 
within the spheroid and GFP-tagged CAFs allowed imaging of 
CAFs invasion in the spheroids.
2. Results
2.1. Stable TNS4 Knockdown CRC Cell Lines
A stable knockdown of TNS4 was achieved by lentiviral trans-
duction of colorectal cell lines, which is demonstrated by 
western blot on Figure  1. Following TNS4 stable knockdown, 
transduction with TdTomato lentivirus allowed us to follow 
the growth of the CRC cell population within the spheroids by 
using a conventional fluorescent plate reader to detect expres-
sion of TdTomato fluorescent protein.
The spheroid formation method used revealed different 
morphologies between CRC cell lines. Whilst DLD1, HT29 and 
HCT116 formed compact spheroids of round uniform shape, 
SW480, and SW620 produced aggregates and LS1034 produced 
a globous irregular shape. (Figure S1, Supporting Information).
2.2. TNS4 Knockdown Reduces Adhesiveness
In the attempt to explain the observed differences in sphe-
roid size and growth we have assessed the ability of shTNS4 
and shLUC CRC cells to adhere to ECM collagen type I, 
which would normally be secreted by CAFs, or CAFs them-
selves, by performing adapted adhesion assays in collagen 
type I coated plates or using CAFs as an adhesion substrate. 
Whereas a tendency for reduced adhesion to collagen type I 
could be observed for all shTNS4 CRC cell lines, the difference 
to shLUC controls was only significant in HT29 (p = 0.0205) 
and SW480 (p  = 0.0245) (Figure  2A). By repeating the adhe-
sion assay over a layer of CAFs, statistically significant reduced 
attachment of shTNS4 versus shLUC was noted for DLD1 (p = 
0.0062), HCT116 (p = 0.0068), HT29 (p = 0.0145), and LS1034 
(p = 0.0284) (Figure 2B).
The reduced adhesion to CAFs upon TNS4 knockdown could 
have an effect in the expansion and paracrine growth signaling 
depending on cell-to-cell contact between CAFs and CRC cells, 
leading to increased fluorescence signal in shTNS4 versus 
shLUC + CAFs  spheroids. Conversely, a reduced spheroid 
volume seen in shTNS4 + CAFs compared to shLUC + CAFs 
could be caused by increased compactness of the CRC cells, 
unsupported by a CAFs scaffold.
2.3. TNS4 Knockdown in 3D Spheroids Affects 
Proliferative Rates
To assess the growth of the CRC cell population within the sphe-
roid, TdTomato fluorescence was measured daily over 7 days.
The SW620ΔCten variant, in which TNS4 was deleted by using 
a CRISPR-Cas9 system, consistently showed increased sphe-
roid growth when compared to its parental SW620 cell line 
(p < 0.0001) (Figure 3A, Table 1A). For both SW480 and LS1034 
cell lines, the shTNS4 variant spheroids showed significantly 
reduced growth when compared to shLUC control spheroids 
(Figure  3B,C). In DLD1, HCT116 and HT29, shTNS4 variants 
produced spheroids with slightly increased proliferation, but 
which was only significant for HCT116 and HT29 (p < 0.0001) 
(Figure 3D,E,F and Table 1D,E,F).
Regarding the influence of CAFs in spheroid growth, a sta-
tistically significant increase in the growth of CRC cells in the 
spheroids was observed in SW620, SW480, and DLD1 when 
comparing shTNS4 variants with or without added CAFs at a 1:1 
proportion (Table  1A,B,D). Interestingly, in LS1034 and HT29 
(Table  1C,F), the promoting effect of CAFs was not seen in 
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Figure 1. A) Western blot and B) respective densitometry showing a decrease in TNS4 expression achieved for shTNS4 stable knockdowns in DLD1 
(62.3%), HT29 (39.4%), HCT116 (68.1%), SW480 (34.1%), and LS1034 (39.42%) cell lines relative to the loading control (β-Actin) and normalized to 
their shLUC (luciferase control, 100%). Two independent protein lysates were tested.
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Figure 2. Adhesion assay of shTNS4 and shLUC CRC cells to A) collagen type I and B) CAFs feeder layer. Mann–Whitney statistical test was performed 
to evaluate differences between shTNS4 and shLUC CRC cells. N = 12 replicates and results shown are representative of two independent experiments. 
Statistically significant p-values are presented on top of the respective shTNS4 bars, in cases where statistically significant differences were not present, 
irrelevant p-values are omitted.
Figure 3. Mean+/− St dev of relative TdTomato fluorescence read-outs (540em–590ex nm) for spheroids composed of colorectal cell lines stably knock-
down for TNS4 (shTNS4), luciferase control (shLUC) with and without addition of cancer-associated fibroblasts (CAFs). Graphs are representative of 
12 replicates per condition and two independent experiments were carried out (the respective statistical analysis for this figure is shown on Table 1).
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shTNS4 spheroids, but only in the presence of normal TNS4 
expression in the shLUC spheroids (Figure 3C,F).
When comparing shTNS4 and shLUC co-cultured with 
CAFs, a significant growth boosting effect can be perceived for 
DLD1, HCT116, and HT29 (Figure 3D–F, Table 1D–F), in which 
spheroids composed of shTNS4 CRC cells with CAFs grow 
more than their control spheroids shLUC with CAFs. In CRC 
cell lines producing loose spheroid aggregates (SW620, SW480, 
and LS1034) this effect is not observed (Figure 3 and Table 1).
Regarding differences observed in terms of whole spheroid 
volume, these could only be measured in those cell lines forming 
round compact spheroids (DLD1, HCT116, and HT29), in which 
the estimation made by approximation to the volume of a sphere 
is valid (Figure S1, Supporting Information, illustrates the sphe-
roid morphology in the different cell lines used in this study). To 
normalize volumetric data, measurements taken on the second 
day were chosen for HCT116 and HT29, as spheroids of these 
cell lines only acquire a compact round shape later than DLD1. 
In HCT116 shTNS4 and shLUC variants as well as in DLD1 
shLUC, addition of CAFs promoted spheroid growth in volume, 
only the difference between DLD1 shTNS4 and DLD1 shTNS4 
+ CAFs was not statistically significant (Figure  4A, Table  2A). 
However, in HT29, addition of CAFs seemed to reduce whole 
spheroid volume, possibly by contraction or increased compact-
ness of the spheroid around CAFs (Figure 4C, Table 2C). When 
grown in low adherence conditions, CAFs form small spheroids 
and do not expand their volume, apparently in a quiescent state 
(Figure 3).
2.4. TNS4 Knockdown Reduced 3D Invasion and Response to 
CAFs-Driven Invasion
By performing 3D invasion assays measuring specific ECM 
degradation without quenching of DQ BSA green we were able 
to isolate matrix invasion from changes in spheroid size due to 
a variation in cell proliferation.
Comparing CRC spheroids, there was a significant decrease 
in 3D invasion in shTNS4 versus shLUC spheroids in both 
DLD1 (p = 0.0434) and HCT116 (p = 0.0281), but not in HT29 
(Figure 5A). In general, addition of CAFs to form mixed pop-
ulation spheroids increased ECM degradation and invasion, 
although this was not always a statistically significant effect. An 
exception to CAFs’ promotion of ECM degradation and inva-
sion was observed with HT29 shTNS4 cells (Figure 5A and D), 
whereas a significant effect was observed for HT29 shLUC 
versus HT29 shLUC + CAFs (p = 0.0070). Interestingly, HT29 
was the only CRC cell line where matrix degradation and inva-
sion in shLUC + CAFs was superior to that of shTNS4 + CAFs 
cells (p = 0.0055), suggesting a particular effect of TNS4 expres-
sion in the interaction with CAFs.
2.5. TNS4 Knockdown Sensitizes CRC Cells to EGFR Inhibition 
Treatment
We and others have shown that TNS4 is an effector of the EFGR-
KRAS-MAPK signaling pathway. This prompted us to investigate 
whether removing TNS4 could affect the activity of anti-EGFR 
drugs such as Gefitinib (which inhibits the kinase domain of 
EGFR). We investigated this in both 2D and 3D models.
Overall, we observed that knockdown of TNS4 resulted in 
increased chemosensitivity to gefitinib in all cell lines. This was 
seen in both assays, but the effect was more pronounced in 3D 
spheroids (Figure 6A,B). Gefitinib treatment alone in shTNS4 
transduced cells reduced expression of EGFR, RAS, and TNS4, 
thereby confirming that TNS4 forms part of this signaling 
pathway (Figure 6C; Figure S2, Supporting Information). Inter-
estingly, TNS4 knockdown resulted in higher EGFR levels than 
in shLUC controls suggesting a negative feedback loop between 
TNS4 and EGFR.
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Table 1. Statistical analysis of TdTomato mean fluorescence readings at 
day 7 for spheroids composed of CRC cell lines with and without CAFs. 
For each condition N  = 12 replicates and results are representative of 
two experiments. Two-way ANOVA statistical test with multiple compari-
sons by Tukey’s test was performed, a p-value <  0.05 was considered 
statistically significant.
Tdtomato relative fluorescence multiple comparisons at day 7
Mean diff. Adjusted p value
A)
SW620 vs. SW620 + CAFs(1:1) −2.085 <0.0001
SW620 vs. SW620DCten −0.8601 <0.0001
SW620DCten vs. SW620DCten + CAFs −1.022 <0.0001
SW620+CAFs vs. SW620DCten + CAFs 0.2036 0.4229
B)
SW480 shTNS4 vs. SW480 shTNS4 + CAFs −0.1476 <0.0001
SW480 shTNS4 vs. SW480 shLUC −0.209 <0.0001
SW480 shTNS4 + CAFs vs. SW480 shLUC + CAFs −0.08405 0.0197
SW480 shLUC vs. SW480 shLUC + CAFs −0.02262 0.8611
C)
LS1034 shTNS4 vs. LS1034shTNS4 + CAFs 0.09316 0.0526
LS1034 shTNS4 vs. LS1034 shLUC −0.1275 0.0029
LS1034shTNS4 + CAFs vs. LS1034 shLUC + CAFs −0.05505 0.4299
LS1034 shLUC vs. LS1034 shLUC + CAFs 0.1657 <0.0001
D)
DLD1 shTNS4 vs. DLD1 shTNS4 + CAFs −0.322 <0.0001
DLD1 shTNS4 vs. DLD1 shLUC 0.03376 0.4726
DLD1 shTNS4 + CAFs vs. DLD1 shLUC + CAFs 0.1275 <0.0001
DLD1 shLUC vs. DLD1 shLUC +CAFs −0.2283 <0.0001
E)
HCT116 shTNS4 vs. HCT116 shTNS4 + CAFs −0.04509 0.8057
HCT116 shTNS4 vs. HCT116 shLUC 0.4322 <0.0001
HCT116 shTNS4 + CAFs vs. HCT116 shLUC + 
CAFs
0.3812 <0.0001
HCT116 shLUC vs. HCT116 shLUC + CAFs −0.0961 0.2243
F)
HT29 shTNS4 vs. HT29 shTNS4 + CAFs 0.0251 0.9859
HT29 shTNS4 vs. HT29 shLUC 0.8126 <0.0001
HT29 shTNS4 + CAFs vs. HT29 shLUC + CAFs 0.2259 0.0176
HT29 shLUC vs. HT29 shLUC + CAFs −0.5616 <0.0001
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3. Discussion
TNS4 overexpression has been reported in a number of 
cancers [3,7,8,24] although in CRC in vitro studies have not shown 
a role for TNS4 in cell proliferation. These were always per-
formed in 2D settings, omitting the presence of an enriched 
tumor microenvironment with increased cell-to-cell interac-
tions and supporting stromal cells. Only recently it has been 
reported that in HeLa cells, TNS4 transient silencing reduced 
cell growth, even though its overexpression had not impact on 
cancer cell proliferation.[25] However, analysis of 3D models 
does take longer and thus we used lentiviral transduction 
with shRNA oligos to produce stable TNS4 knockdowns. This 
allowed spheroid growth to be monitored for 7 days.
We first tested for changes in adhesiveness to both acellular 
stroma composed of collagen type I and CAFs followingTNS4 
knockdown. We observed that shTNS4 transfected cells show sig-
nificantly reduced adhesion to CAFs and slightly decreased adhe-
sion to collagen type I, This effect could be due to a disturbance 
in molecular mechanosensors where TNS4 is located.[26]The 
receptor for collagen type I, a integrin α1β1 heterodimer, has 
its expression controlled by C-Myc and this is one of the events 
regulating cancer progression.[27,28] It is possible that at different 
stages of their neoplastic progression, as HT29 and SW480 
undergo TNS4 knockdown, expression of integrin α1β1 heterodi-
mers is deregulated, resulting in significantly reduced adhesive-
ness to collagen type I. Adhesion of CRC cells to CAFs might 
also be mediated by the multi-molecular adhesome of integrin 
B1 heterodimers. The cytoplasmic tails of integrins are bound to 
the C-terminus phosphotyrosine-binding domain of TNS4 which 
in turn forms a complex with several other proteins including 
actin.[29–32] Therefore, it is possible that removing TNS4 protein 
by gene knockdown could disturb the stability of the integrin B1 
adhesome and its ability to bind to CAF-secreted fibronectin.
We next tested whether TNS4 expression could affect cell 
proliferation in spheroid models. Interestingly it appears to vary 
according to the spheroid morphology produced. In SW620, 
SW480, and LS1034, which naturally produce irregular shaped 
and loose spheroids when grown in 3D, a reduction in TNS4 
expression resulted in decreased cell proliferation. In contrast, 
HCT116 and HT29, which naturally produce tight spheroids, 
shTNS4 transduction caused a significant increase in prolif-
eration. The data were consistent for both fluorescence meas-
urements and spheroid volumetric analysis indicating that the 
observations were not technical artefacts. This change in cell 
Adv. Biosys. 2020, 4, 2000031
Figure 4. Volumetric measurements of spheroid growth in A) DLD1, B) HCT116, and C) HT29 CRC cell lines and representative images of spheroids 
composed of shTNS4/shLUC variants with or without added CAFs at day 7 (The respective statistical analysis for this figure is shown on Table 2).
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proliferation observed in compact spheroids could be related 
to the effects on spheroid compactness and cell adhesiveness 
by disturbing molecular mechanosensors at the focal adhesion 
complex where TNS4 is situated and altering focal adhesion 
kinase (FAK)-related contact inhibition. An association between 
phosphorylated FAK and nuclear TNS4 expression has been 
previously reported in metastases of CRC cases,[33] and it was 
suggested that the two pathways may interact. It is possible that 
the fine balance existing between the extracellular matrix and 
cell-to-cell interactions, FAK activation could be influenced by a 
downregulation of TNS4 to alter cell proliferation.[34]
When CAFs were added to the spheroid cultures, as docu-
mented in other studies, this supported growth of CRC cells 
thereby validating our 3D spheroid co-culture model.[17] Inter-
estingly, in this context, a growth advantage is also seen for 
shTNS4 + CAFs in cell lines forming compact spheroids 
(DLD1, HCT116, and HT29), but not in loose spheroids formed 
by SW620, SW480, and LS1034. This data could suggest a novel 
role for TNS4 in intercellular interactions. Integrins have been 
reported to form heterotypic complexes with adhesion mole-
cules in adjacent cells and this may form part of a contact inhi-
bition mechanism.[29] Alternatively, the explanation may lie in 
differences in the diffusion rates of CAF-secreted growth fac-
tors, such as TGFß,[35] in tight versus loose spheroids.
When investigating invasion and matrix degradation of 3D 
spheroids, we observed that, in two cell lines, knockdown of 
TNS4 replicated the data seen in 2D analysis. Validating the 
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Table 2. Statistical analysis of volume measurements at day 7 for sphe-
roids composed of CRC cell lines with and without CAFs. For each 
condition N = 12 replicates and results are representative of two experi-
ments. Two-way ANOVA statistical test with multiple comparisons by 
Tukey’s test was performed, a p-value < 0.05 was considered statistically 
significant.
Volumetry multiple comparisons at day 7
Mean diff. Adjusted p value
A)
DLD1 shTNS4 vs. DLD1 shTNS4 + CAFs −0.1372 0.9321
DLD1 shTNS4 vs. DLD1 shLUC 1.86 <0.0001
DLD1 shTNS4 + CAFs vs. DLD1 shLUC + CAFs −0.7782 <0.0001
DLD1 shLUC vs. DLD1 shLUC + CAFs −2.775 <0.0001
B)
HCT116 shTNS4 vs. HCT116 shTNS4+CAFs −1.801 <0.0001
HCT116 shTNS4 vs. HCT116 shLUC −0.7325 <0.0001
HCT116 shTNS4 + CAFs vs. HCT116 shLUC + 
CAFs
−1.911 <0.0001
HCT116 shLUC vs. HCT116 shLUC + CAFs −2.979 <0.0001
C)
HT29 shTNS4 vs. HT29 shTNS4+CAFs 0.832 <0.0001
HT29 shTNS4 vs. HT29 shLUC −0.5574 <0.0001
HT29 shTNS4 + CAFs vs. HT29 shLUC + CAFs −0.2921 <0.0001
HT29 shLUC vs. HT29 shLUC + CAFs 1.097 <0.0001
Figure 5. A) 96h measurement of extracellular matrix degradation in 3D spheroid invasion assay using DQ BSA green. Mann–Whitney t-test was used 
for comparisons between two groups of non-parametric data. Exact p-values shown are representative of two independent experiments. Where non-
indicated, differences where non-significant. Representative images of Z-stack slice of 3D spheroids for B) DLD1, C) HCT116, and D) HT29. In B, C, D, 
upper row depicts DQ BSA green fluorescence and lower row a projection of the maximum intensity of all slices in the confocal microscopy Z-stack.
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effects of TNS4 in these more sophisticated models supports the 
role of TNS4 in carcinogenesis. When CAFs were added to the 
3D spheroids, as expected, increased invasiveness was observed. 
This effect has been explained by CAFs-directed assembly 
of fibronectin and induction of integrins αV and β3.[36] Fur-
thermore, CAFs have also been described to increase contrac-
tility and traction forces in the ECM, mediated by non-muscle 
myosin II and platelet-derived growth factor α, which are then 
transmitted through α5β1 integrin to produce an alignment of 
the fibronectin matrix. Aligned fibronectin matrix features in 
invasion sites in prostatic and pancreatic carcinomas.[37] The 
effect of TNS4 knockdown in the co-culture model was broadly 
in-line with the effect seen in the 3D monoculture in as much 
as there was a reduction in matrix degradation but it was not 
quite as marked. Interestingly, in HT29, whilst the monoculture 
had shown no effect following TNS4 knockdown, in the 3D co-
culture, invasion was significantly reduced in shTNS4 + CAFs 
spheroids when compared to shLUC + CAFs. These observa-
tions were made on several repeated experiments although we 
do not currently have an explanation, but suspect it could be due 
to the wild-type status of KRAS gene in HT29 and its different 
EGFR signaling potency.
Given our previous data demonstrating the involvement of 
TNS4 in EGFR/KRAS/MAPK signaling,[5,38,39] we have used 
our model to test this in 3D spheroids. We also tested whether 
TNS4 could modulate the activity of anti-EGFR therapies by 
using gefitinib, which is an inhibitor of the EGFR kinase 
domain. Our results show a reduction of TNS4 levels with 
gefitinib treatment, thereby confirming TNS4 is part of this 
pathway and suggesting the blockade of EGFR tyrosine kinase 
domain could lead to TNS4 increased degradation.
It has been shown that TNS4 stabilizes EGFR by reducing its 
ligand-induced degradation via a reduction in its ubiquitination, 
but not EGF-induced tyrosine phosphorylation of EGFR.[40] In 
shTNS4 spheroids, EGFR would be more unstable and easily 
degraded upon ligand-binding. Lower levels of active EGFR 
would also lead to increased sensitivity to its inhibitor gefitinib, 
which we have observed in DLD1 and HT29. By performing 
gefitinib chemosensitivity test using shTNS4 and shLUC 
cells, we have observed a reduction in cell viability with TNS4 
knockdown in both 2D and 3D conditions. This supports the 
notion that TNS4 is an important downstream component of 
the EGFR signaling pathway and raises the possibility of an 
anti-TNS4 therapy being used in combination with anti-EGFR 
Adv. Biosys. 2020, 4, 2000031
Figure 6. Chemosensitivity of shTNS4 and shLUC CRC cell lines in A) 2D and B) 3D conditions. Western blot protein detection of EGFR, TNS4, TNS3, 
Src, and Ras in shTNS4 and shLUC CRC cells, treated with Gefitinib 50 µm for 24 h and respective controls, in two samples obtained from independent 
experiments. p-values indicating statistically significant differences are marked by *(p < 0.05) or **(p < 0.01).
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therapies. A recent study has also demonstrated that TNS4 is 
significantly downregulated by cetuximab (anti-EGFR immuno-
therapy) and put forward the possibility that TNS4 suppression 
could be used in cetuximab-refractory CRC patients with KRAS 
activating mutations.[41]
We recognize that the 3D spheroid tumor microenviron-
ment we have created with heterotypic interactions between 
CRC cells and CAFs is far from being ideal and the presence of 
immune cells and permeable vasculature would be an impor-
tant addition to our model. Other types of models, such as 
patient-derived recellularized CRC scaffolds[21,42] or well-defined 
hydrogel-based spheroids[43] may be useful alternatives to rec-
reate the CRC tumor microenvironment in vitro, as well as 
those with the addition of lymphoid[44] or endothelial[45] cells to 
increase the model complexity.
In summary, we have hereby used a novel methodology to 
mimic an enriched 3D colorectal tumor microenvironment 
and demonstrate a role for TNS4 in the dynamics of cell adhe-
sion, 3D spheroid proliferation, invasion and EGFR inhibitor 
resistance. These results suggest TNS4 has a valuable role as 
an effector in early stage metastasis, likely associated with its 
mechanosensing properties and involvement in heterotypic 
interactions at the focal adhesion complex. Furthermore, TNS4 
inhibition might improve the efficacy of anti-EGFR therapy, by 
increasing its chemosensitivity.
4. Experimental Section
Cell Culture: CAFs were isolated from human colon carcinoma 
resection specimens following 2.4 U mL−1 dispase and 100 U mL−1 
collagenase type II (both from Invitrogen) disaggregation of tumor 
fragments and digestion for 2 h at 37 °C. Cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented 
with 20% heat-inactivated fetal bovine serum (FBS, Gibco), 2  mm 
L-glutamine, 0.1% hydrocortisone (w/v), 0.75% bovine insulin (w/v).
All cell lines used in this study were obtained from the American 
Tissue Culture Collection (ATCC) and used for experiments up to 
passage 30. SW620ΔCten is derived from SW620 submitted to TNS4 
deletion by CRISPR-Cas9.[46]
HEK293T, DLD1, HCT116, SW480, SW620, SW620ΔCten were 
maintained in 2D cell culture in DMEM (Gibco) supplemented with 10% 
heat-inactivated FBS (Gibco), 2 mm L-glutamine and incubated at 37 °C, 
5% CO2. Cells were regularly passaged by dissociation with Trypsin- 
Ethylenediaminetetraacetic acid (Trypsin-EDTA) 0.25% (Sigma Aldrich) 
every 2–3 days.
HT29 was maintained in McCoys 5A medium supplemented with 
10% FBS and 2  mm L-glutamine. LS1034 was maintained in Roswell 
Park Memorial Institute (RPMI) 1640 supplemented with 10% FBS 
and 2  mm L-glutamine. Gefitinib (Sigma Aldrich, Y001813) was diluted 
to the concentration of 100  mm in dimethyl sulfoxide (DMSO) and 
subsequently dissolved in cell culture media to concentrations of 50 and 
25 µm. Cell viability was measured in six replicates, by using a Fluorostar 
Omega plate fluorescence plate reader (540  nm excitation, 590  nm 
emission) after incubation with 10% Presto Blue (Life Technologies) for 
1 h at 37 °C, 5% CO2.
Lentivirus Production and Transduction: The lentiviral plasmid 
components were acquired from Addgene: Transfer plasmids: Rix-
PGK-Tom-W (#25 813), FUGW (#14 883), and PLKO.1 TRC (# 10 878); 
Packaging plasmid: psPAX2 (#12 260) and Envelope: pMD2.G (#12 259).
The short hairpin RNA (shRNA) for TNS4 and LUC (Luciferase) 
knockdown were selected from the RNAi consortium shRNA library (https://
www.broadinstitute.org/rnai-consortium/rnai-consortium-shrna-library).
The shRNA oligos (Table S1, Supporting Information) were annealed 
at 95 °C for 4  min in a PCR thermal cycler and slowly cooled down 
overnight. The annealed oligos were phosphorylated, ligated into 
pLKO.1-TRC, transformed in chemocompetent E.coli (New England 
Biolabs), isolated by miniprep, and double-digested with restriction 
enzymes AgeI and EcoRI (both New England Biolabs). Correctly inserted 
oligos were confirmed by restriction enzyme double-digestion of the 
resulting vectors with EcoRI and NcoI and Sanger sequencing.
Viral particles were packaged in HEK293T cells seeded at a 
density of 1.5  ×  106 per 10  cm petri dishes in a proportion of 24  µL 
Fugene 6 (Promega, E2691) in 136  µL serum-reduced OPTI-MEM 
(Gibco, Invitrogen) to 2  µg pLKO.1 shRNA plasmid: 1500  ng psPAX2 
packaging plasmid (Addgene #12  260): 500  ng pMD2.G envelope 
plasmid (Addgene #12  259) to 40  µL serum-reduced OPTI-MEM. 
72 h after transfection, shRNA lentiviruses were concentrated by 
ultracentrifugation at 10 000 × g, 4 °C, 4 h in a 10% sucrose buffer.[47] 
Lentivirus titers were examined by Lenti-go stix quick test (Takara Bio, 
631 280) according to the manufacturers’ instructions, using the freely 
mobile app (Lenti-X GoStix) to determine titer concentrations.
CRC cell lines were first transduced with PLKO.1 shTNS4/shLUC 
lentivirus and selected with Puromycin (Sigma Aldrich, p8833) at a 
dose that killed 100% of non-transduced control cells over a 7-day 
period, followed by transduction with TdTomato lentivirus at excessive 
multiplicity of infection (MOI) to ensure complete transduction efficiency. 
Cancer-associated fibroblasts were transduced with FUGW lentivirus 
to induce EGFP expression also at excessive MOI. Maintenance of 
complete transduction efficiency was routinely inspected by observation 
of TdTomato and EGFP expression across several passages, using a 
wide-field Nikon TiE fluorescence microscope.
Protein Extraction and Western Blot: Cells were washed with ice-cold 
PBS and incubated on ice for 10  min with radioimmunoprecipitation 
assay (RIPA) buffer (Invitrogen) with protease and phosphatase 
inhibitor (Pierce, ThermoFisher) diluted to 1x. Resulting cell lysates were 
centrifuged at 16 000g, at 4 °C for 30 min and the supernatant transferred 
to a new eppendorf tube. A bicinchoninic acid assay (BCA) assay was 
performed to determine protein quantification of the supernatant.
For Western blotting, 40 µg of protein mixed with 25%(v/v)NuPAGE 
LDS Sample buffer(4x) and 10%(v/v)reducing sample buffer (10x) were 
denatured at 95 °C for 5 min, incubated in ice for 5 min and then loaded 
into to a pre-cast gel (NuPAGE 4–12% Bis-Tris Protein Gels, Invitrogen). 
Gel electrophoresis was performed for 90  min at 125  V. The resulting 
gel was immunoblotted onto a nitrocellulose membrane (Amersham, 
GE Healthcare Life Sciences) at 25  V for 30  min, using the Trans-Blot 
Transfer system (BIO-RAD).
After confirming transfer by Ponceau Red staining, the membrane 
was blocked with 5% skimmed milk (Sigma-Aldrich) in tris-buffered 
saline (TBS) for 1 hour with gentle agitation at room temperature. The 
membrane was then incubated overnight with primary antibodies at 4 °C 
with gentle agitation (dilutions and suppliers listed on supplementary 
table 2) and then washed 3  ×  5  min with tris-buffered saline, 0.1% 
tween 20 (TBST). The hybridized membrane was incubated with the 
respective IRDYE-conjugated secondary antibody (Donkey anti-mouse 
or anti-rabbit 800CW) for 1 h at room temperature, using the blocking 
solution as the diluent. The membrane was further washed 3 × 5 min in 
TBST and infra-red fluorescence detected with the Li-Cor Oddissey Blot 
scanner. Densitometry of the western blot bands was performed with 
Image studio lite software (LI-COR). Original imaged blots are shown in 
the negative image of the captured fluorescence light for better contrast 
without incurring in any modifications that could biase the perceived 
band intensity.
3D Spheroid Formation, Volumetry, and Fluorescence Readings: Cell 
suspensions of the TdTomato expressing colorectal cell lines, their 
shTNS4 and shLUC expressing variants, were seeded in 12-replicates in 
Ultra-low attachment 96-well plates (CLS4515, Corning) at 2.0 × 104cells 
mL−1 in a final volume of 100  µL alone or in a 1:1 mix with CAFs, in 
Fluorobrite DMEM supplemented with 10% FBS and 4 mm L-glutamine. 
The plates were centrifuged at 200  g for 5  min, at acceleration 7 
and deceleration 7 in a Megafuge 16 centrifuge (ThermoScientific). 
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Spheroid or aggregate formation was confirmed in 24–48 h and daily 
measurements of fluorescence were taken in a Fluostar Omega plate 
reader (BMG labtech) set to perform bottom readings, at 544  nm 
excitation and 590  nm emission wavelength, gain 2500. Fluorescence 
readings were normalized to day 1 to account for initial differences in 
seeded cell numbers. Brightfield images of spheroids were taken daily for 
volumetry quantification using a widefield inverted microscope (Nikon 
TiE). Volumetry analysis was performed using Image J Wand tracing tool 
in eight-connected mode to determine the area of each spheroid. Mean 
spheroid radius was determined by assuming an approximation to the 
area of the circle and from there inferred the volume of the spheroid, as 
an approximation to the volume of a sphere.
Adhesion Assays: Adhesion assays to collagen type I and CAFs were 
performed to assess adhesiveness of shTNS4 cells versus its shLUC 
control. 96-well flat bottom plates (Costar) were coated with 100 uL of 
0.3 mg mL−1 of rat tail collagen type I (Corning) diluted in PBS, 0.02M 
NaHO. Plates were incubated overnight at 37 °C. For adhesion to CAFs, 
96 well plates were seeded with 1000 CAFs per well and incubated 
overnight at 37 °C. CRC cell lines were added to coated or CAF seeded 
plates at a density of 2.0 × 104 cells per well, and incubated for 2 h. Half 
of the wells containing shTNS4 and shLUC cells were washed 3x with 
PBS and then incubated with complete fluorobrite DMEM for 15  min. 
Fluorescence values at 544–590  nm excitation-emission were read in a 
Fluostar Omega plate reader. After subtracting background fluorescence, 
a ratio of washed to non-washed was used to determine cell adhesion.
3D Spheroid Invasion Assay: At day 3 of spheroid formation, spheroids 
were transferred to a chilled flat-bottomed 96-well plate coated with 
50 uL per well of Cultrex BME RGF (Trevigen) at 6 mg mL−1 and overlaid 
with another 50 uL per well of Cultrex and 100 uL of complete Fluorobrite 
DMEM supplemented with 80  ng mL−1 human recombinant EGF as a 
chemoattractant. For extracellular matrix degradation analysis, DQ BSA-
Green was added to Cultrex at 30 ug mL−1 as previously described.[48]
Spheroids were imaged at 96 h of invasion by confocal microscopy, 
performing Z-stacks with 3 µm thick slices using 488  and 568  nm 
lasers. The volume of each fluorescent component was calculated on 
Image J given by multiplying the thresholded area (obtained by the 
Otsu method on the Image J threshold menu options) of each slice by 
its thickness, using a macro plugin freely available from http://www.
optinav.info/MeasureStack.htm. A ratio of the measured DQ BSA green 
per TdTomato fluorescent volume was used as an estimation of ECM 
degradation normalized to the volume of cancer cells.
Statistical Analysis: Analysis of proliferation and volumetry assays 
was performed on GraphPad Prism version 7 by two-way ANOVA with 
multiple mean comparisons by Tukey test. Comparisons between two 
groups of non-parametric values were performed by Mann–Whitney test. 
Statistical significance was considered for values of p < 0.05.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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